PMID- 36067948
OWN - NLM
STAT- MEDLINE
DCOM- 20230214
LR  - 20230214
IS  - 2666-9919 (Electronic)
IS  - 2666-9919 (Linking)
VI  - 53
IP  - 1
DP  - 2023 Feb
TI  - Intra-abdominal abscesses: Microbiological epidemiology and empirical 
      antibiotherapy.
PG  - 104604
LID - S2666-9919(22)00181-6 [pii]
LID - 10.1016/j.idnow.2022.08.005 [doi]
AB  - PURPOSE: Data on the microbiological epidemiology of Intra-Abdominal Abscesses 
      (IAAs) are very scarce. We aimed to study the microbiological epidemiology of 
      these infections in order to optimize empirical antibiotic therapy. PATIENTS AND 
      METHODS: Between January 2015 and December 2020, we retrospectively analyzed all 
      IAAs files in our hospital. Clinical and microbiological data such as antibiotic 
      susceptibilities were collected. RESULTS: We studied 243 IAA cases. All in all, 
      139 (57.2%) IAAs were healthcare-associated and 201 (82.7%) were drained. The 
      highest risk situations for IAAs were appendicitis (n = 69) and diverticulitis 
      (n = 37). Out of the 163 microbiologically documented infections, 136 (81.9%) 
      were polymicrobial. Enterobacterales (n = 192, 36.1%), Enterococcus sp. (n = 84, 
      17.6%) and anaerobes (n = 66, 16.1%) were the most frequently identified 
      bacteria. Gram-negative bacteria were susceptible to amoxicillin-acid clavulanic, 
      piperacillin-tazobactam, cefotaxime, meropenem in 55.2%, 84.9%, 77.6% and 99.5% 
      of cases, respectively. Concerning Gram-positive bacteria, the susceptibility 
      rate was 81.8% for amoxicillin-clavulanic acid, piperacillin-tazobactam and 
      meropenem, and decreased to 63.4% for cefotaxime. CONCLUSION: This study 
      highlights the polymicrobial profile of IAAs and their low susceptibility to 
      amoxicillin and clavulanic acid. The piperacillin-tazobactam association remained 
      the most appropriate empirical antibiotic therapy.
CI  - Copyright (c) 2022 Elsevier Masson SAS. All rights reserved.
FAU - Mechai, F
AU  - Mechai F
AD  - Infectious Disease Department, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, 
      Bobigny, France; IAME, INSERM UMR 1137, Universite Sorbonne Paris Nord, Sorbonne 
      Paris Cite, France. Electronic address: frederic.mechai@aphp.fr.
FAU - Kolakowska, A
AU  - Kolakowska A
AD  - Infectious Disease Department, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, 
      Bobigny, France.
FAU - Carbonnelle, E
AU  - Carbonnelle E
AD  - IAME, INSERM UMR 1137, Universite Sorbonne Paris Nord, Sorbonne Paris Cite, 
      France; Clinical Microbiology Department, Groupe Hospitalier Paris Seine 
      Saint-Denis, AP-HP, Bobigny, France.
FAU - Bouchaud, O
AU  - Bouchaud O
AD  - Infectious Disease Department, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, 
      Bobigny, France.
FAU - Tresallet, C
AU  - Tresallet C
AD  - Visceral Surgery Department, Avicenne Hospital, Bobigny, France.
FAU - Jaureguy, F
AU  - Jaureguy F
AD  - IAME, INSERM UMR 1137, Universite Sorbonne Paris Nord, Sorbonne Paris Cite, 
      France; Clinical Microbiology Department, Groupe Hospitalier Paris Seine 
      Saint-Denis, AP-HP, Bobigny, France.
LA  - eng
PT  - Journal Article
DEP - 20220905
PL  - France
TA  - Infect Dis Now
JT  - Infectious diseases now
JID - 101775152
RN  - FV9J3JU8B1 (Meropenem)
RN  - 157044-21-8 (Piperacillin, Tazobactam Drug Combination)
RN  - 804826J2HU (Amoxicillin)
RN  - N2GI8B1GK7 (Cefotaxime)
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Humans
MH  - Meropenem
MH  - Retrospective Studies
MH  - Piperacillin, Tazobactam Drug Combination/therapeutic use
MH  - *Amoxicillin
MH  - Cefotaxime
MH  - Anti-Bacterial Agents/therapeutic use
MH  - *Abdominal Abscess/drug therapy/epidemiology
OTO - NOTNLM
OT  - Antibiotic susceptibility
OT  - Intra-abdominal abscess
OT  - Microbiological epidemiology
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/09/07 06:00
MHDA- 2023/02/15 06:00
CRDT- 2022/09/06 19:26
PHST- 2022/05/30 00:00 [received]
PHST- 2022/07/29 00:00 [revised]
PHST- 2022/08/29 00:00 [accepted]
PHST- 2022/09/07 06:00 [pubmed]
PHST- 2023/02/15 06:00 [medline]
PHST- 2022/09/06 19:26 [entrez]
AID - S2666-9919(22)00181-6 [pii]
AID - 10.1016/j.idnow.2022.08.005 [doi]
PST - ppublish
SO  - Infect Dis Now. 2023 Feb;53(1):104604. doi: 10.1016/j.idnow.2022.08.005. Epub 
      2022 Sep 5.